vs
Masco（MAS）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
Masco的季度营收约是登士柏西诺德的2.0倍（$1.9B vs $961.0M），Masco净利率更高（11.9% vs -15.2%，领先27.1%），Masco同比增速更快（6.5% vs 6.2%），过去两年登士柏西诺德的营收复合增速更高（0.4% vs -4.2%）
美国家居建材企业Masco主营家装及新建住宅市场相关产品，旗下拥有20余家子公司，在全球运营近80座生产工厂，其中美国本土近60座，海外地区超20座。公司1969年于纽交所挂牌上市，后实现快速增长，成功跻身美国财富500强榜单。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
MAS vs XRAY — 直观对比
营收规模更大
MAS
是对方的2.0倍
$961.0M
营收增速更快
MAS
高出0.3%
6.2%
净利率更高
MAS
高出27.1%
-15.2%
两年增速更快
XRAY
近两年复合增速
-4.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $961.0M |
| 净利润 | $228.0M | $-146.0M |
| 毛利率 | 35.8% | 46.1% |
| 营业利润率 | 16.5% | -14.5% |
| 净利率 | 11.9% | -15.2% |
| 营收同比 | 6.5% | 6.2% |
| 净利润同比 | 14.5% | 66.0% |
| 每股收益（稀释后） | — | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MASXRAY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $961.0M | ||
| Q3 25 | $1.9B | $904.0M | ||
| Q2 25 | $2.1B | $936.0M | ||
| Q1 25 | $1.8B | $879.0M | ||
| Q4 24 | $1.8B | $905.0M | ||
| Q3 24 | $2.0B | $951.0M | ||
| Q2 24 | $2.1B | $984.0M |
净利润MASXRAY
| Q1 26 | $228.0M | — | ||
| Q4 25 | $165.0M | $-146.0M | ||
| Q3 25 | $189.0M | $-427.0M | ||
| Q2 25 | $270.0M | $-45.0M | ||
| Q1 25 | $186.0M | $20.0M | ||
| Q4 24 | $182.0M | $-430.0M | ||
| Q3 24 | $167.0M | $-494.0M | ||
| Q2 24 | $258.0M | $-4.0M |
毛利率MASXRAY
| Q1 26 | 35.8% | — | ||
| Q4 25 | 33.9% | 46.1% | ||
| Q3 25 | 34.2% | 48.8% | ||
| Q2 25 | 37.6% | 52.4% | ||
| Q1 25 | 35.8% | 53.0% | ||
| Q4 24 | 34.8% | 49.3% | ||
| Q3 24 | 36.6% | 52.1% | ||
| Q2 24 | 37.5% | 51.9% |
营业利润率MASXRAY
| Q1 26 | 16.5% | — | ||
| Q4 25 | 13.8% | -14.5% | ||
| Q3 25 | 15.8% | -24.1% | ||
| Q2 25 | 20.1% | -13.7% | ||
| Q1 25 | 15.9% | 7.2% | ||
| Q4 24 | 15.9% | -56.2% | ||
| Q3 24 | 18.0% | -48.6% | ||
| Q2 24 | 19.0% | 5.1% |
净利率MASXRAY
| Q1 26 | 11.9% | — | ||
| Q4 25 | 9.2% | -15.2% | ||
| Q3 25 | 9.9% | -47.2% | ||
| Q2 25 | 13.2% | -4.8% | ||
| Q1 25 | 10.3% | 2.3% | ||
| Q4 24 | 10.0% | -47.5% | ||
| Q3 24 | 8.4% | -51.9% | ||
| Q2 24 | 12.3% | -0.4% |
每股收益（稀释后）MASXRAY
| Q1 26 | — | — | ||
| Q4 25 | $0.81 | $-0.74 | ||
| Q3 25 | $0.90 | $-2.14 | ||
| Q2 25 | $1.28 | $-0.22 | ||
| Q1 25 | $0.87 | $0.10 | ||
| Q4 24 | $0.85 | $-2.09 | ||
| Q3 24 | $0.77 | $-2.46 | ||
| Q2 24 | $1.17 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $326.0M |
| 总债务越低越好 | $2.9B | $2.3B |
| 股东权益账面价值 | $27.0M | $1.3B |
| 总资产 | $5.2B | $5.4B |
| 负债/权益比越低杠杆越低 | 109.07× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资MASXRAY
| Q1 26 | — | — | ||
| Q4 25 | $647.0M | $326.0M | ||
| Q3 25 | $559.0M | $363.0M | ||
| Q2 25 | $390.0M | $359.0M | ||
| Q1 25 | $377.0M | $398.0M | ||
| Q4 24 | $634.0M | $272.0M | ||
| Q3 24 | $646.0M | $296.0M | ||
| Q2 24 | $398.0M | $279.0M |
总债务MASXRAY
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.9B | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MASXRAY
| Q1 26 | $27.0M | — | ||
| Q4 25 | $-185.0M | $1.3B | ||
| Q3 25 | $-78.0M | $1.5B | ||
| Q2 25 | $-84.0M | $2.0B | ||
| Q1 25 | $-254.0M | $2.0B | ||
| Q4 24 | $-279.0M | $1.9B | ||
| Q3 24 | $-88.0M | $2.5B | ||
| Q2 24 | $-26.0M | $3.1B |
总资产MASXRAY
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.2B | $5.4B | ||
| Q3 25 | $5.3B | $5.7B | ||
| Q2 25 | $5.3B | $6.1B | ||
| Q1 25 | $5.1B | $6.0B | ||
| Q4 24 | $5.0B | $5.8B | ||
| Q3 24 | $5.3B | $6.6B | ||
| Q2 24 | $5.4B | $6.9B |
负债/权益比MASXRAY
| Q1 26 | 109.07× | — | ||
| Q4 25 | — | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $101.0M |
| 自由现金流经营现金流 - 资本支出 | — | $60.0M |
| 自由现金流率自由现金流/营收 | — | 6.2% |
| 资本支出强度资本支出/营收 | 1.8% | 4.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $104.0M |
8季度趋势，按日历期对齐
经营现金流MASXRAY
| Q1 26 | — | — | ||
| Q4 25 | $418.0M | $101.0M | ||
| Q3 25 | $456.0M | $79.0M | ||
| Q2 25 | $306.0M | $48.0M | ||
| Q1 25 | $-158.0M | $7.0M | ||
| Q4 24 | $407.0M | $87.0M | ||
| Q3 24 | $416.0M | $141.0M | ||
| Q2 24 | $346.0M | $208.0M |
自由现金流MASXRAY
| Q1 26 | — | — | ||
| Q4 25 | $371.0M | $60.0M | ||
| Q3 25 | $415.0M | $40.0M | ||
| Q2 25 | $270.0M | $16.0M | ||
| Q1 25 | $-190.0M | $-12.0M | ||
| Q4 24 | $351.0M | $36.0M | ||
| Q3 24 | $378.0M | $98.0M | ||
| Q2 24 | $303.0M | $156.0M |
自由现金流率MASXRAY
| Q1 26 | — | — | ||
| Q4 25 | 20.7% | 6.2% | ||
| Q3 25 | 21.6% | 4.4% | ||
| Q2 25 | 13.2% | 1.7% | ||
| Q1 25 | -10.5% | -1.4% | ||
| Q4 24 | 19.2% | 4.0% | ||
| Q3 24 | 19.1% | 10.3% | ||
| Q2 24 | 14.5% | 15.9% |
资本支出强度MASXRAY
| Q1 26 | 1.8% | — | ||
| Q4 25 | 2.6% | 4.3% | ||
| Q3 25 | 2.1% | 4.3% | ||
| Q2 25 | 1.8% | 3.4% | ||
| Q1 25 | 1.8% | 2.2% | ||
| Q4 24 | 3.1% | 5.6% | ||
| Q3 24 | 1.9% | 4.5% | ||
| Q2 24 | 2.1% | 5.3% |
现金转化率MASXRAY
| Q1 26 | — | — | ||
| Q4 25 | 2.53× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 1.13× | — | ||
| Q1 25 | -0.85× | 0.35× | ||
| Q4 24 | 2.24× | — | ||
| Q3 24 | 2.49× | — | ||
| Q2 24 | 1.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAS
暂无分部数据
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
